NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria
- PMID: 40801595
- PMCID: PMC12345861
- DOI: 10.3390/cells14151162
NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria
Abstract
Cerebral malaria (CM) is the severe progression of an infection with Plasmodium falciparum, causing detrimental damage to brain tissue and is the most frequent cause of Plasmodium falciparum mortality. The critical role of brain-infiltrating CD8+ T cells in the pathophysiology of CM having been revealed, our investigation focuses on the role of NR2F6, an established immune checkpoint, as a candidate driver of CM pathology. We employed an experimental mouse model of CM based on Plasmodium berghei ANKA (PbA) infection to compare the relative susceptibility of Nr2f6-knock-out and wild-type C57BL6/N mice. As a remarkable result, Nr2f6 deficiency confers a significant survival benefit. In terms of mechanism, we detected less severe endotheliopathy and, hence, less damage to the blood-brain barrier (BBB), accompanied by decreased sequestered parasites and less cytotoxic T-lymphocytes within the brain, manifesting in a better disease outcome. We present evidence that NR2F6 deficiency renders mice more resistant to experimental cerebral malaria (ECM), confirming a causal and non-redundant role for NR2F6 in the progression of ECM disease. Consequently, pharmacological inhibitors of the NR2F6 pathway could be of use to bolster BBB integrity and protect against CM.
Keywords: CD8+ T cell brain infiltration; compromised blood–brain barrier (BBB) integrity; experimental cerebral malaria (ECM); group F; innovative pharmacological therapy solution for CM; member 6 (NR2F6); nuclear receptor subfamily 2.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
IFNγ-inducible Gbp4 and Irgb6 contribute to experimental cerebral malaria pathology in the olfactory bulb.mBio. 2025 Aug 13;16(8):e0124925. doi: 10.1128/mbio.01249-25. Epub 2025 Jul 3. mBio. 2025. PMID: 40607809 Free PMC article.
-
ZIF-8 with encapsulated dihydroartemisinin in a drug delivery system for protection against Plasmodium berghei ANKA-induced experimental cerebral malaria in C57BL/6N mice.Microbiol Spectr. 2025 Jul;13(7):e0236624. doi: 10.1128/spectrum.02366-24. Epub 2025 Jun 11. Microbiol Spectr. 2025. PMID: 40497684 Free PMC article.
-
Antimalarial and neuroprotective effects of ethanolic extracts of the five-flower remedy in an experimental cerebral malaria model.PLoS One. 2025 Sep 2;20(9):e0330880. doi: 10.1371/journal.pone.0330880. eCollection 2025. PLoS One. 2025. PMID: 40892845 Free PMC article.
-
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.Cochrane Database Syst Rev. 2014 Jun 30;(6):CD008152. doi: 10.1002/14651858.CD008152.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152. doi: 10.1002/14651858.CD008152.pub4. PMID: 24979199 Free PMC article. Updated.
-
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152. doi: 10.1002/14651858.CD008152.pub4. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2018 Feb 02;2:CD008152. doi: 10.1002/14651858.CD008152.pub5. PMID: 25693791 Free PMC article. Updated.
References
-
- WHO World malaria World malaria report report. Lancet Microbe. 2023;6:101073. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials